Drug Pipeline Database & Screener

Over 2000 drug entries from about 550 biotech companies in Phase 2, 3 or NDA development.

Company SCREENER also available to filter through financial and clinical data. Financial filters include market cap, short ratio, price to book and relative volume, while you can also run a filter according to the development stage of the drug (e.g. Phase 2, PDUFA date).

NASDAQ and NYSE stocks only are shown. OTC stocks are not covered on BioPharmCatalyst.

Subscribe HERE to ensure you receive your weekly free copy of the BioPharmCatalyst Biotech Watchlist and/or our daily option of Biotech Price Movers and Pipeline Database updates.

Financial data are delayed 15-25 minutes.

Showing companies
Screener
Sort
Stage
Indication
Market Cap
Price
Short ratio
Relative Volume
Price to book
Company
Price
Change
No of Shares
Market Cap
Short Ratio
Updated
$82.86
-1.06  -1.27%
1.8 billion
$146.2 billion
1.62
10/27/2020
Tap to view 60 drugs
Drug Indication Stage News
Botox Forehead lines Approved Approval (third indication) announced October 3, 2017.
Depatuxizumab mafodotin ABT-414 Glioblastoma (rGBM) Phase 3 Phase 3 trial did not meet primary endpoint at interim analysis - May 17, 2019.
Veliparib Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) Phase 3 Phase 3 trial did not meet primary endpoints - April 19, 2017.
Ibrutinib Relapsed or refractory MCL mantle cell lymphoma Approved Approved November 13, 2013.
Imbruvica Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy Approved Approved February 12, 2014.
Imbruvica Deletion 17p Approved Approved July 19, 2014.
VIEKIRA PAK HCV - genotype 1 Approved Approved December 19, 2014.
IMBRUVICA Waldenström’s Macroglobulinemia Approved Approved January 29, 2015 - PCYC
ABBV-8E12 Alzheimer's disease Phase 2 Phase 2 initiation announced January 25, 2017.
ATOGEPANT Chronic migraine Phase 3 Phase 3 trial met primary endpoint - July 29, 2020.
RELAMORELIN Diabetic Gastroparesis Phase 3 Phase 3 top-line data due 2020.
Cenicriviroc (CVC) Nonalcoholic steatohepatitis (NASH) Phase 3 Phase 3 data due 2021.
ABICIPAR Age-related macular degeneration (AMD) CRL CRL issued June 26, 2020.
Oxymetazoline HCl cream 1.0% Facial Erythema (Redness) Associated with Rosacea Approved Approved January 19, 2017.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) Approved Approved September 14, 2017.
Venclexta (MURANO) Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) Approved Approval announced June 11, 2018.
Venetoclax - CANOVA Relapsed or refractory multiple myeloma Phase 3 Phase 3 data due in 2021.
Risankizumab Psoriasis Approved FDA approval announced April 23, 2019.
Imbruvica Second-line Chronic graft-versus-host disease (GVHD) Approved Approval announced August 2, 2017.
ABT-494 Psoriatic Arthritis Phase 3 Phase 3 trial to commenced 2017.
Rova-T (TRINITY) Third-line Small Cell Lung Cancer Phase 2 Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.
Upadacitinib Atopic Dermatitis sNDA Filing Regulatory filing announced October 19, 2020.
Imbruvica Marginal zone lymphoma Approved sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Glecaprevir/Pibrentasvir (G/P) Hepatitis C virus (HCV) Approved Approval announced August 3, 2017.
Elagolix Uterine Fibroids Approved FDA approval announced May 29, 2020.
Elagolix Endometriosis Approved FDA approval announced July 24, 2018.
Ubrogepant Migraine Approved FDA Approval announced December 23, 2019.
ABT-494 upadacitinib Rheumatoid arthritis Approved FDA Approval announced August 16, 2019.
Rova-T (TAHOE) Second-line Small Cell Lung Cancer Phase 3 Phase 3 enrolment to be stopped due to shorted overall survival following recommendation from Independent Data Monitoring Committee (IDMC) December 5, 2018.
Rova-T (MERU) First-line Small Cell Lung Cancer Phase 3 Phase 3 trial demonstrated no survival benefit at interim analysis - October 29, 2019.
Imbruvica and Gazyva - iLLUMINATE Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) Approved FDA approval announced January 28, 2019.
IMBRUVICA (ibrutinib) Waldenström’s Macroglobulinemia Approved FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib) Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
Venclexta First line unfit AML Approved FDA approval announced November 21, 2018.
Upadacitinib - U-ACHIEVE Ulcerative colitis Phase 2/3 Phase 2b data released October 22, 2018 - primary endpoint met. Phase 3 trial initiation announced October 2018.
Venetoclax and obinutuzumab Chronic Lymphocytic Leukemia Phase 3 FDA approval announced May 15, 2019.
Ibrutinib (Imbruvica) Pancreatic cancer Phase 3 Phase 3 primary endpoint not met (PFS/OS).
Venclexta BELLINI Multiple myeloma Phase 3 Phase 3 primary endpoint met.
Botox Lower limb spasticity Approved FDA Approval announced October 24, 2019.
Botox Upper limb spasticity Approved FDA Approval announced June 21, 2019.
Venetoclax and obinutuzumab Chronic lymphocytic leukemia sNDA Filing sNDA filing announced June 4, 2019.
Juvéderm VOLUMA Mid-Face Injection Via Cannula Approved FDA Approval announced September 3, 2019.
Veliparib Ovarian cancer Phase 3 Phase 3 presentation at ESMO 28 September 2019.
Risankizumab ( LIMMITLESS ) Psoriasis Phase 3 Phase 3 data presented at EADV October 10, 2019.
IMBRUVICA (ibrutinib) and rituximab Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Approved FDA Approval announced April 21, 2020.
Risankizumab vs secukinumab Plaque psoriasis Phase 3 Phase 3 trial met primary endpoint - January 14, 2020.
Upadacitinib Psoriatic arthritis PDUFA sNDA filing announced June 1, 2020. PDUFA estimate April 1, 2021.
Risankizumab MOTIVATE Crohn’s Disease Phase 3 Phase 3 data due 2020.
Risankizumab KEEPSAKE2 Psoriatic Arthritis Phase 3 Phase 3 data due 2020.
Risankizumab vs secukinumab Psoriasis Phase 3 Phase 3 data due 2020.
Upadacitinib Atopic dermatitis Phase 3 Phase 3 data met co-primary endpoints - June 18, 2020. Second Phase 3 trial also met primary endpoint - July 21, 2020.
Venclexta (VIALE-A) Acute Myeloid Leukemia (AML) Approved FDA approval announced October 16, 2020.
Imbruvica + Venclexta (CAPTIVATE) Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma Phase 2 Phase 2 data due 2020.
Ibrutinib in combination with prednisone Chronic Graft Versus Host Disease Phase 3 Phase 3 data due 2020.
ABBV-951 Parkinson's disease Phase 3 Phase 3 data due late-2021.
Ibrutinib COVID-19 Phase 2 Phase 2 trial has been initiated.
JUVÉDERM VOLUMA Augmentation of the chin region Approved FDA Approval announced June 15, 2020.
Botox Neurogenic Detrusor Overactivity PDUFA sBLA filing accepted June 22, 2020. PDUFA date 1Q 2021.
Cenicriviroc + Otezla (apremilast) + Firazyr (icatibant) COVID-19 (severe) Phase 2 Phase 2 trial initiation announced August 3, 2020.
RINVOQ (upadacitinib) Active Ankylosing Spondylitis PDUFA sNDA filing announced August 25, 2020. PDUFA estimate June 25, 2020.
$1.19
-0.07  -5.56%
84.8 million
$100.9 million
10/27/2020
Tap to view 4 drugs
Drug Indication Stage News
ABO-101 Sanfilippo syndrome type B (MPS IIIB) Phase 1/2 Phase 1/2 presentation at WORLDSymposium February 12, 2020 noted trial has been well-tolerated to date, with no treatment-related severe adverse events.
EB-101 Recessive dystrophic epidermolysis bullosa (RDEB) Phase 3 Phase 3 enrollment to be completed early-2021.
ABO-102 Sanfilippo syndrome type A (MPS IIIA) Phase 1/2 Phase 1/2 enrollment to be completed by end of 2020.
ABO-202 CLN1 disease (Infantile Batten disease) Phase 1/2 Phase 1/2 trial planned.
$3.96
-0.04  -1.00%
9.3 million
$36.8 million
10/27/2020
Tap to view 2 drugs
Drug Indication Stage News
Gencaro Chronic Heart Failure Phase 3 Phase 3 trial to be initiated in 2021 subject to financing.
AB201 COVID-19 Phase 2b Phase 2b trial to be initiated 4Q 2020. Top-line data due 2Q 2021.
$2.93
+0.1  +3.53%
84.1 million
$246.3 million
10/27/2020
Tap to view 3 drugs
$46.52
+1.65  +3.67%
158.9 million
$7.4 billion
10/27/2020
Tap to view 8 drugs
Drug Indication Stage News
Pimavanserin - CLARITY-2 and CLARITY-3 Adjunctive Treatment in Patients With Major Depressive Disorder Phase 3 Phase 3 trial did not meet primary endpoint - July 20, 2020.
Pimavanserin - Advance-2 Adjunctive treatment in patients with negative symptoms of schizophrenia Phase 3 Phase 3 trial initiated 3Q 2020.
Pimavanserin - Enhance Adjunctive treatment of schizophrenia Phase 3 Phase 3 data did not meet primary endpoint - July 22, 2019.
Pimavanserin - SERENE Alzheimer’s disease agitation Phase 2 Announced October 4, 2017 that trial will be discontinued.
Pimavanserin Parkinson’s disease psychosis (PDP) Approved Approved April 29 2016. Additional dose approval announced June 29, 2018.
Pimavanserin - Harmony Alzheimer’s disease psychosis PDUFA PDUFA date April 3, 2021.
Trofinetide Rett Syndrome Phase 3 Phase 3 data due 2H 2021.
ACP-044 Pain Phase 2 Phase 2 trial to be initiated 1H 2021.
$2.63
-0.09  -3.47%
11.9 million
$31.3 million
10/27/2020
Tap to view 5 drugs
Drug Indication Stage News
EDSIVO Vascular Ehlers-Danlos Syndrome CRL CRL issued June 25, 2019.
Tovaxin (Tcelna) Secondary Progressive MS (SPMS) Phase 2b Phase 2b trial did not meet primary endpoint - October 28, 2016.
ACER-001 Urea cycle disorder (UCD) NDA Filing NDA filing due 1H 2021.
Osanetant induced Vasomotor Symptoms (iVMS) Phase 1/2 Phase 1/2 trial to be initiated 1H 2021.
Emetine COVID-19 Phase 2/3 Phase 2/3 trial to be initiated 1H 2021.
$12.20
+0.22  +1.84%
19.6 million
$239 million
10/27/2020
Tap to view 1 drug
Drug Indication Stage News
ADI-001 Non-Hodgkin’s lymphoma Phase 1 Phase 1 IND has been cleared for initiation. Data due 2021.
$8.21
-0.15  -1.76%
3.6 million
$29.5 million
10/27/2020
Tap to view 1 drug
Drug Indication Stage News
Cytisine - ORCA-2 Smoking cessation Phase 3 Phase 3 trial initiation announced October 7, 2020.
$4.95
+0.1  +1.96%
71.7 million
$354.8 million
10/27/2020
Tap to view 8 drugs
Drug Indication Stage News
Crenezumab - CREAD 2 Alzheimer’s disease Phase 3 Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Semorinemab Alzheimer’s disease Phase 2 Phase 2 top-line data did not meet endpoints - September 23, 2020.
ACI-24 (anti-Abeta vaccine) Alzheimer's disease-like characteristics in individuals with Down syndrome Phase 1b Phase 1b presentation at AAIC July 29, 2020.
Crenezumab - CREAD 1 Alzheimer’s disease Phase 3 Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Semorinemab - LAURIET Alzheimer’s disease Phase 2 Phase 2 trial ongoing as of September 23, 2020.
ACI-3024 Alzheimer’s disease Phase 1 Phase 1 data due 2H 2020.
ACI-35.030 Alzheimer’s Disease Phase 1/2 Phase 1b/2 interim analysis 2H 2020. Initiation of the second highest dosing group announced July 16, 2020.
ACI-24 Alzheimer’s disease (AD) Phase 2 Phase 2 12-month analysis due 2H 2020.
$0.87
-0.03  -3.56%
48 million
$41.6 million
10/27/2020
Tap to view 4 drugs
Drug Indication Stage News
Ampyra Improve walking in patients with multiple sclerosis Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
Tozadenant Parkinson’s disease (PD) Phase 3 Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Company noted November 20, 2017 that program will be discontinued.
Dalfampridine Post stroke deficits Phase 3 Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
INBRIJA (CVT-301) OFF episodes of Parkinson’s disease (PD) Approved FDA Approval announced December 22, 2018.
$4.02
-0.08  -1.95%
42.8 million
$172.2 million
10/27/2020
Tap to view 9 drugs
Drug Indication Stage News
ATI-502 (ATI-50002-AA-201) - dose ranging Alopecia areata Phase 2 Phase 2 data did not meet primary endpoint - June 26, 2019.
ATI-502 (VITI-201 Topical) Vitiligo Phase 2 Development to be discontinued - noted August 8, 2019.
ATI-501 (AUAT-201 Oral) Alopecia areata Phase 2 Phase 2 data met primary endpoint and some secondary endpoints - July 30, 2019. Partner required for further development.
ESKATA (hydrogen peroxide) Seborrheic keratosis (SK) Approved Approval announced December 15, 2017.
A-101 THWART-1 and THWART-2 Common warts (verruca vulgaris) Phase 3 Phase 3 data met all endpoints - September 16, 2019 and October 24, 2019.
ATI-502 Androgenetic alopecia (AGA) - Hair loss Phase 2 Partner required to further development.
ATI-450 Rheumatoid arthritis (RA) Phase 2a Phase 2a data due 1H 2021.
ATI-1777 Atopic dermatitis Phase 1/2 Phase 1/2 initiation of dosing announced October 20, 2020.
ATI-450 COVID-19 Phase 2a Phase 2a dosing commenced August 2020.
$1.75
+0.04  +2.40%
90.3 million
$158.2 million
10/27/2020
Tap to view 3 drugs
Drug Indication Stage News
ARX-04 (SAP302) Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury Phase 3 Phase 3 data released August 15 2016
DSUVIA (ARX-04) Moderate-to-severe acute pain following a surgical procedure Approved FDA Approval announced November 2, 2018.
Zalviso Post-operative pain following open abdominal surgery and hip or knee replacement surgery Phase 3 CRL Jul 26 2014. NDA resubmission planned.
$0.20
  +-0.65%
96.9 million
$19.3 million
10/27/2020
Tap to view 1 drug
$4.79
-0.09  -1.75%
154.6 million
$739.8 million
10/27/2020
Tap to view 5 drugs
Drug Indication Stage News
MAGE-A4 (ADP-A2M4) Solid tumors Phase 1 Phase 1 durability and translational data from patients with synovial sarcoma due at a medical conference 2H 2020.
AFP (ADP-A2AFP) Hepatocellular carcinoma Phase 1 Phase 1 presentation at ILC noted 1/9 complete responses, 6/9 stable disease, 2/9 progressive disease.
MAGE-A10 (ADP-A2M10) Non-Small Cell Lung Cancer (NSCLC) Phase 1 Phase 1 enrolment completed 2019.
MAGE-A4 (SPEARHEAD‑1) Synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) Phase 2 Phase 2 enrolment to be completed 1H 2021.
MAGE-A4 (ADP-A2M4CD8 - SURPASS) Solid tumors Phase 1 Phase 1 dose update at SITC meeting November 11, 2020.
$27.02
+0.3  +1.14%
76.7 million
$2.1 billion
5.83
10/27/2020
Tap to view 4 drugs
Drug Indication Stage News
Camidanlumab tesirine Hodgkin lymphoma (HL) Phase 2 Phase 2 interim data due 1H 2021.
Loncastuximab tesirine and Ibrutinib - LOTIS 2 Diffuse large B-cell lymphoma (DLBCL) Phase 2 Phase 2 data June 12, 2020 noted overall response rate of 48.3%, a complete response rate of 24.1%.
Loncastuximab Tesirine Diffuse Large B-Cell Lymphoma / Mantle Cell Lymphoma BLA Filing BLA filing announced September 21, 2020.
Camidanlumab Tesirine Solid Tumors Phase 1b Phase 1b data released at ESMO September 17, 2020.
$1.80
  +0.01%
13.8 million
$24.8 million
10/27/2020
Tap to view 1 drug
$2.13
-0.07  -2.95%
86.3 million
$184.4 million
10/27/2020
Tap to view 2 drugs
Drug Indication Stage News
ASCENIV (RI-002) Primary Immune Deficiency Diseases Approved FDA Approval announced April 1, 2019.
BIVIGAM Primary humoral immunodeficiency CRL Response to Complete Response Letter submitted January 7, 2019.
$0.76
-0.04  -4.79%
93.7 million
$71.2 million
10/27/2020
Tap to view 5 drugs
Drug Indication Stage News
Epinephrine Pre-filled Syringe (PFS) Emergency treatment of anaphylaxis. Approved CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
APC-1000 Asthma/COPD Phase 2 Phase 3 development on hold - noted May 9, 2019.
Symjepi - low dose Anaphylaxis Approved FDA Approval announced September 27, 2018.
ZIMHI (naloxone HCI Injection) Opioid overdose PDUFA CRL announced November 25, 2019. NDA resubmitted with new PDUFA date of November 15, 2020.
APC-8000 (sublingual tadalafil) Erectile dysfunction NDA Filing Refusal to file letter received February 26, 2019.
$3.50
+0.01  +0.29%
28.3 million
$99 million
10/27/2020
Tap to view 4 drugs
Drug Indication Stage News
GOCOVRI (amantadine) Multiple sclerosis (MS) Phase 3 Phase 3 data met primary endpoint at one of two doses. Secondary endpoint in walking impairment not met. Second trial will not be initiated as a result of data - December 17, 2019. Findings were confirmed June 17, 2020.
Namzaric Moderate to severe dementia of the Alzheimer's type. Approved Approved December, 24 2014.
GOCOVRI (ADS-5102) Levodopa-Induced Dyskinesia + Parkinson's disease patients receiving levodopa and experiencing OFF episodes PDUFA FDA Approval announced August 24, 2017. PDUFA date February 1, 2021 for sNDA to include treatment of OFF episodes in PD patients receiving levodopa.
GOCOVRI (amantadine) Dyskinesia patients with Parkinson's disease Phase 3 Phase 3 open-label data released April 19, 2018.
$2.10
-0.05  -2.19%
9.5 million
$19.9 million
10/27/2020
Tap to view 1 drug
Drug Indication Stage News
ADi Psoriasis Phase 1/2 Phase 1/2 trial planned.
$12.20
+0.32  +2.69%
97.3 million
$1.2 billion
10/27/2020
Tap to view 4 drugs
Drug Indication Stage News
ADVM-043 Alpha-1 Antitrypsin (A1AT) Deficiency Phase 1/2 Development to be discontinued - noted November 1, 2018.
AVA-101 Wet age-related macular degeneration (Wet-AMD) Phase 2a Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
ADVM-022 (OPTIC) Wet age-related macular degeneration (Wet-AMD) Phase 1 Phase 1 updated data to be presented November 13, 2020 at AAO meeting.
ADVM-022 - INFINITY Diabetic macular edema Phase 2 Phase 2 randomization of first patient announced July 13, 2020 with data due 2H 2021.
$0.39
-0.04  -8.71%
66.2 million
$26.1 million
10/27/2020
Tap to view 8 drugs
Drug Indication Stage News
Axalimogene filolisbac + durvalumab Recurrent or refractory HPV-associated cervical cancer and head & neck cancer Phase 1/2 Enrollment to be terminated - noted November 2, 2018.
ADXS-PSA and Keytruda - KEYNOTE-046 Castrate-resistant prostate cancer Phase 1/2 Phase 1 presentation at ASCO Genitourinary Cancers Symposium February 13, 2020 noted median overall survival (95% CI) of 33.7 months.
Axalimogene filolisbac - AIM2CERV Trial High-risk, locally advanced cervical cancer Phase 3 Phase 3 trial closed - noted June 27, 2019.
ADXS-HER2 HER2-driven malignancies - cancer Phase 1b Decided not to proceed to the expansion phase of the trial - noted in 10K December 21, 2017.
Axalimogene filolisbac Anal cancer (FAWCETT) Phase 2 Noted in 10-K December 21, 2017 that it will not initiate the Stage 2 portion of the trial in order to focus its resources on other clinical priorities.
ADXS-NEO Non-small cell lung cancer (NSCLC) Phase 1 Phase 1 safety and immunogenicity data presented at AACR March 2019
ADXS-503 Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 data to be presented at SITC meeting November 12, 2020. Noted October 26, 2020 overall response rate of 17% (1/6 patients).
ADXS-504 Prostate Cancer Phase 1 Phase 1 trial to be initiated 4Q 2020.
$9.95
+0.14  +1.38%
46.5 million
$462.6 million
10/27/2020
Tap to view 6 drugs
Drug Indication Stage News
Roclatan Glaucoma Approved FDA Approval announced March 12, 2019.
Rhopressa Glaucoma Approved PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017.
AR-13503 Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) Phase 1/2 Phase 1/2 trial initiation announced August 20, 2019.
AR-1105 Macular edema due to RVO (retinal vein occlusion) Phase 2 Phase 2 top-line data July 27, 2020 noted treatment was well tolerated with no unexpected safety findings with sustained treatment effects.
Roclatan - Mercury 3 Open Angle Glaucoma Phase 3 Phase 3 top-line data released September 24, 2020. Non-inferiority to Ganfort achieved.
AR-15512 (AVX-012) Dry eye disease Phase 2b Phase 2b trial to be initiated 4Q 2020 with top-line data due 3Q 2021.
$0.35
  +-0.80%
53.5 million
$21.7 million
10/27/2020
Tap to view 3 drugs
Drug Indication Stage News
Macimorelin Acetate - Macrilen Adult Growth Deficiency Approved CRL issued November 2014. Approval announced following resubmission December 20, 2017.
Zoptrex Endometrial cancer Phase 3 Phase 3 trial did not meet primary endpoint - May 1, 2017.
Macimorelin acetate (AEZS-130) Paediatric patients with suspected growth hormone deficiency (GHD) Phase 3 Phase 3 trial to commence 1Q 2021.
$3.31
+0.1  +3.12%
84.5 million
$279.7 million
10/27/2020
Tap to view 6 drugs
Drug Indication Stage News
AFM13 with Keytruda Hodgkin Lymphoma - Cancer Phase 1b Phase 1b updated data at ICML June 22, 2019 noted ORR of 88% at highest dose, CR rates of 42%-46%.
AFM13 Hodgkin Lymphoma - Cancer Phase 2 Phase 2a ongoing.
AFM13 CD30-positive peripheral T cell lymphoma (PTCL) Phase 2 Phase 2 interim analysis due mid-2021.
AFM11 Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL) Phase 1 Phase 1 program terminated - noted May 22, 2019.
AFM24 EGFR-expressing solid tumors Phase 1/2 Phase 1/2a completion of first cohort announced June 17, 2020. Noted no efficacy yet was observed, however, efficacy was not expected at this dose level.
AFM13 + NK cells CD30-positive lymphomas Phase 1 Phase 1 initiation of dosing announced October 6, 2020.
$3.85
+0.2  +5.48%
183.4 million
$706.3 million
10/27/2020
Tap to view 5 drugs
$39.00
+1.52  +4.06%
69.1 million
$2.7 billion
10/27/2020
Tap to view 16 drugs
Drug Indication Stage News
AG-348 - Mitapivat Thalassemia Phase 2 Phase 2 updated data at EHA June 12, 2020. Primary endpoint defined as a ≥1.0 g/dL increase in Hb concentration from baseline at 1 or more assessments between week 4 and week 12 was met by 12 of 13 (92.3%) patients.
Ivosidenib IDH1m Relapsed/Refractory AML - cancer Approved FDA Approval announced July 20, 2018.
AG-348 (ACTIVATE-T) Pyruvate kinase deficiency Phase 3 Phase 3 data due between the end of 2020 and mid-2021.
AG-120 and VIDAZA - AGILE Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer Phase 3 Phase 3 enrolment to be completed 2021.
IDHIFA (enasidenib) - AG-221 Advanced hematologic malignancies with an IDH2 mutation Approved Approval announced August 1, 2017.
AG-120 Ivosidenib (ClarIDHy) IDH1 mutant positive cholangiocarcinoma - cancer sNDA Filing sNDA filing due 1Q 2021
Enasidenib or ivosidenib with VIDAZA Frontline AML with IDH1 or IDH2 mutation Phase 1/2 Phase 1 updated data February 25, 2019 noted ORR of 78%, 57% CR rate, and 12-month Survival Rate of 82%.
AG-270 Solid tumors Phase 1 Phase 1 enrolment has slowed due to COVID-19. A go/no-go decision is expected no later than 2022.
Vorasidenib (AG-881) Glioma Phase 3 Phase 3 enrolment has slowed as a result of COVID-19.
Ivosidenib Frontline AML with IDH1 mutation Approved FDA Approval announced May 2, 2019.
Vorasidenib (AG-881) IDHm low-grade glioma Phase 1 Phase 1 presentation at ASCO May 29, 2020. Median Progression-free Survival of 31.4 months.
Ivosidenib IDH1 mutant newly diagnosed AML ineligible for standard therapies Phase 1 Phase 1 updated data at ASCO June 3, 2019. 30% CR rate.
Ivosidenib and azacitidine ( Vidaza) Newly diagnosed AML with an IDH1 mutation Phase 1 Phase 1 updated data at ASH December 9, 2019 noted complete response (CR) rate of 61% and a CR + CR with partial hematologic recovery (CRh) rate of 70%.
AG-348 - Mitapivat (ACTIVATE) Pyruvate Kinase Deficiency Phase 3 Phase 3 data due between the end of 2020 and mid-2021.
AG-348 - Mitapivat (ASH) Sickle cell disease. Phase 2 Phase 2 data due at ASH December 2020.
AG-946 Healthy volunteers Phase 1 Phase 1 trial to commence 3Q 2020.
$7.85
+0.6  +8.28%
44.6 million
$350.1 million
10/27/2020
Tap to view 3 drugs
Drug Indication Stage News
Pegzilarginase (AEB1102) Arginase I deficiency Phase 3 Phase 3 data due 1Q 2021.
Pegzilarginase (AEB1102) + KEYTRUDA Small cell lung cancer (SCLC) Phase 2 Phase 1/2 trial ongoing.
ACN00177 Homocystinuria Phase 1/2 Phase 1/2 trial initiated June 2020.
$2.96
+0.09  +2.96%
87.4 million
$258.4 million
10/27/2020
Tap to view 1 drug
Drug Indication Stage News
Twirla Contraceptive patch Approved FDA Approval announced February 14, 2020.
$5.35
+0.07  +1.33%
25.9 million
$138.3 million
10/27/2020
Tap to view 3 drugs
Drug Indication Stage News
AAV Gene Therapy Achromatopsia Phase 1/2 Phase 1/2 interim data due 4Q 2020.
rAAV-hRS1 X-linked retinoschisis (XLRS) Phase 1/2 Phase 1/2 interim data released December 12, 2018. No signs of clinical activity.
AGTC-501 X-linked Retinitis Pigmentosa (XLRP) Phase 1/2 Phase 1/2 12-month data due 4Q 2020.
$2.09
+0.01  +0.49%
39.7 million
$83 million
0.43
10/27/2020
Tap to view 6 drugs
Drug Indication Stage News
Ampligen CFS CRL CRL February 4, 2013.
Ampligen, Intron A, celecoxib and pembrolizumab Triple-Negative Breast Cancer Phase 1 All patients have been treated or are near completion of treatment - August 2020.
Ampligen, Intron A, and celecoxib Colorectal cancer Phase 2 Phase 2 trial ongoing.
Ampligen, cisplatin and pembrolizumab Ovarian cancer Phase 2 Phase 2 trial is enrolling - noted August 2020.
Ampligen, Intron A Prostate Cancer Phase 2 Phase 2 trial has been initiated - noted August 2020.
Ampligen and interferon alpha-2b COVID-19 Phase 1/2 Phase 1/2a trial commencement of recruitment announced September 16, 2020.
$34.49
  +0.00%
65.5 million
$2.3 billion
10/27/2020
Tap to view 4 drugs
Drug Indication Stage News
PALFORZIA - AR101 Peanut Allergy Approved FDA approval announced January 31, 2020.
AR 201 Egg Allergy Phase 2 Phase 2 data due 1H 2021.
AR101 with adjunctive dupilumab Peanut Allergy Phase 2 Phase 2 trial initiation announced October 15, 2018. Ongoing as of July 30, 2020.
AR101 POSEIDON Peanut Allergy Phase 3 Phase 3 data due 2021.
$2.38
-0.46  -16.02%
143.3 million
$341.8 million
10/27/2020
Tap to view 5 drugs
Drug Indication Stage News
Auryxia Hyperphosphatemia Approved Approved Sept 5, 2014.
Vadadustat - INNO2VATE Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD) Phase 3 Phase 3 data met primary endpoints - May 5, 2020.
Vadadustat - PRO2TECT Non-dialysis patients with anemia related to CKD (NDD-CKD) Phase 3 Phase 3 trial met efficacy primary endpoint but did not meet primary safety MACE endpoint.
Auryxia Iron deficiency anemia in non-dialysis dependent CKD patients Approved sNDA FDA Approval announced November 7, 2017.
Vadadustat COVID-19 Phase 3 Phase 3 initiation announced July 14, 2020.
$2.07
-0.12  -5.48%
8.7 million
$18.1 million
10/27/2020
Tap to view 1 drug
Drug Indication Stage News
VLP vaccine COVID-19 vaccine Phase 1 Pre-clinical trials are planned with clinical trials to be potentially initiated after.
$26.43
+0.17  +0.65%
34.7 million
$917.1 million
10/27/2020
Tap to view 1 drug
$1.68
  +0.00%
33.9 million
$56.9 million
10/27/2020
Tap to view 5 drugs
Drug Indication Stage News
Nomacopan Paroxysmal nocturnal hemoglobinuria (PNH) Phase 3 Phase 3 interim data January 10, 2020 noted all patients achieved the primary endpoint of transfusion independence. Additional data due 4Q 2020.
Nomacopan Atopic keratoconjunctivitis Phase 1/2 Phase 1/2 interim data released September 1, 2020.
Nomacopan (Coversin) Bullous Pemphigoid Phase 2 Phase 2 trial met primary endpoint - May 2020. Full data to be presented at EADV meeting October 29, 2020. Phase 3 trial to commence 1H 2021.
Nomacopan Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) Phase 3 Phase 3 enrollment to commence 4Q 2020.
Nomacopan COVID-19 Phase 2 U.S randomized clinical studies to commence 4Q 2020. Brazil trial has commenced.
$19.89
+0.59  +3.06%
34.4 million
$683.6 million
10/27/2020
Tap to view 1 drug
Drug Indication Stage News
AK-OTOF Hearing loss Phase 1/2 Phase 1/2 trial to commence in 2021.
$32.64
-0.38  -1.15%
19 million
$619.9 million
10/27/2020
Tap to view 4 drugs
Drug Indication Stage News
Odevixibat (A4250) - PEDFIC- 1 Progressive familial intrahepatic cholestasis (PFIC) Phase 3 Phase 3 top-line data met primary endpoints - September 8, 2020.
Elobixibat Nonalcoholic steatohepatitis (NASH) Phase 2 Phase 2 trial met primary endpoint. However, development in NASH will not continue - August 18, 2020.
Odevixibat (A4250) Biliary atresia Phase 3 Phase 3 commencement of enrolment announced July 14, 2020.
Odevixibat Alagille syndrome Phase 3 Phase 3 trial to commence by the end of 2020.
$7.02
-0.25  -3.40%
38.6 million
$271.3 million
10/27/2020
Tap to view 9 drugs
Drug Indication Stage News
ADX-102 - Reproxalap Dry eye syndrome Phase 3 Phase 3 (Part 1) data December 3, 2019 noted one co-primary endpoint was met while the other missed. Top-line results from the first of the RASP trials are expected by the end of 2020.
Reproxalap (ADX-102) Allergic conjunctivitis Phase 2/3 Phase 3 data due 1H 2021. Phase 2 new data to be presented at AAO meeting from November 11, 2020.
ADX-102 reproxalap Noninfectious anterior uveitis Phase 3 Phase 3 data did not meet endpoints - June 25, 2019.
Reproxalap (ADX-102) Sjögren-Larsson Syndrome (SLS) Phase 3 Development placed on hold - noted March 12, 2020.
ADX-1612 (ganetespib) Post-transplant lymphoproliferative disorder Phase 2 Development placed on hold - noted March 12, 2020.
ADX-2191 Proliferative vitreoretinopathy (PVR) Phase 3 Phase 3 enrolment delayed due to COVID-19.
ADX-629 Psoriasis and atopic asthma Phase 2 Phase 2 trial planned for 4Q 2020.
ADX-629 COVID-19 Phase 2 Phase 2 trial to be initiated.
ADX-1612 Ovarian cancer Phase 2 Phase 2 enrolment to be completed in June 2020.
$9.93
+0.12  +1.17%
79.3 million
$786.7 million
10/27/2020
Tap to view 4 drugs
Drug Indication Stage News
AL001 Frontotemporal Dementia Phase 3 Phase 3 commencement of dosing announced July 24, 2020.
AL002 Alzheimer’s disease Phase 1b Phase 2 trial to be initiated 2H 2020.
AL003 Alzheimer’s disease Phase 1 Phase 1b trial ongoing.
AL101 Healthy volunteers Phase 1 Phase 1 initiation of dosing announced January 6, 2020.
$15.22
+0.42  +2.84%
36.9 million
$561.5 million
10/27/2020
Tap to view 1 drug
Drug Indication Stage News
ALG-01013 Hepatitis B Phase 1 Phase 1 trial initiated August 2020 (New Zealand).
$4.39
-0.04  -0.85%
5 million
$22.1 million
10/27/2020
Tap to view 1 drug
Drug Indication Stage News
Iluvien Diabetic macular edema Approved CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
$15.96
+0.05  +0.31%
159 million
$2.5 billion
10/27/2020
Tap to view 12 drugs
Drug Indication Stage News
Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD) Schizophrenia Approved FDA approval announced July 2, 2018.
ALKS 3831 (olanzapine/samidorphan) Schizophrenia, bipolar PDUFA PDUFA date November 15, 2020. Advisory Committee Meeting October 9, 2020 that samidorphan meaningfully mitigates olanzapine-associated weight gain (16 yes, 1 no) and that the safety profile of ALKS 3831 has been adequately characterized (13 yes, 3 no, 1 abstention).
BYDUREON Type 2 diabetes Approved CRL received March 15, 2010.
Aristada Schizophrenia Approved Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
Diroximel fumarate (BIIB098) Multiple sclerosis (MS) Approved FDA Approval announced October 30, 2019.
ALKS 5461 Major depressive disorder CRL CRL announced February 1, 2019.
ALKS 3831 - ENLIGHTEN-1 Schizophrenia Phase 3 Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
ALKS 4230 ARTISTRY-1 Solid tumors Phase 1 Phase 1/2 data presented at ESMO September 18, 2020. 1/5 partial responses in melanoma cohort (monotherapy).
Aristada and Invega Sustenna Schizophrenia Phase 3 Phase 3 data released April 9, 2019 - primary endpoint met.
ALKS 4230 + Keytruda - ARTISTRY-2 Solid tumors Phase 1 Phase 1 data presented at SITC November 8, 2019.
Diroximel fumarate (BIIB098) - Head-to-head trial versus Tecfidera - Relapsing Remitting Multiple Sclerosis (RRMS) Phase 3 Phase 3 top-line data met primary endpoint - July 30, 2019.
ALKS 4230 (ARTISTRY-3) Solid Tumors Phase 3 Phase 2 trial initiation announced August 18, 2020.
$93.86
+2.8  +3.07%
48.9 million
$4.6 billion
10/27/2020
Tap to view 6 drugs
Drug Indication Stage News
AK002 Severe Allergic Conjunctivitis Phase 1b Phase 1b presentation at ASCRS May 16, 2020.
AK002 Indolent Systemic Mastocytosis Phase 1 Phase 1 data released February 19, 2019.
AK002 Chronic Urticaria Phase 2 Phase 2 additional data released February 11, 2019. 9% UAS7 complete responder rate.
Antolimab (AK002) Eosinophilic Gastritis Phase 3 Phase 3 top-line data due 2H 2021.
Antolimab (AK002) Eosinophilic esophagitis Phase 2/3 Phase 2/3 top-line data due 2H 2021.
Antolimab (subcutaneous) Healthy Volunteers Phase 1 Phase 1 data released October 26, 2020 - safe and well tolerated.
$35.97
+0.21  +0.59%
139.3 million
$5 billion
10/27/2020
Tap to view 6 drugs
Drug Indication Stage News
UCART19 (PALL) Acute lymphoblastic leukemia (ALL) Phase 1 Phase 1 trial ongoing.
UCART19 - CALM Refractory B-cell Acute Lymphoblastic Leukaemia Phase 1 Phase 1 trial ongoing.
ALLO-715 - UNIVERSAL Multiple myeloma Phase 1/2 Phase 1/2 data due 4Q 2020.
ALLO-501 - ALPHA Non-Hodgkin lymphoma (NHL) Phase 1 Phase 1 further data due late 2020 or early 2021.
ALLO-715 with nirogacestat Multiple myeloma Phase 1 Phase 1 trial to commence 2H 2020.
ALLO-501A (ALPHA2) Large B-cell lymphoma Phase 1 Phase 1 trial initiated 2Q 2020.
$1.31
  +0.00%
38.1 million
$49.9 million
10/27/2020
Tap to view 4 drugs
Drug Indication Stage News
Reloxaliase ALLN-177 (URIROX-1) Enteric Hyperoxaluria Phase 3 Phase 3 trial met primary endpoint, key secondary endpoint missed - November 7, 2019.
Reloxaliase ALLN-177 (Study 206) Primary hyperoxaluria Phase 2 Phase 2 presentation at ASN November 8, 2019.
Reloxaliase ALLN-177 (URIROX-2) Enteric Hyperoxaluria Phase 3 Phase 3 interim analysis due 1Q 2022 and top-line data 3Q 2022.
ALLN-346 Hyperuricemia Phase 1 Phase 1 initial data due 4Q 2020.
$127.00
-1.67  -1.30%
116 million
$14.7 billion
10/27/2020
Tap to view 15 drugs
Drug Indication Stage News
Givosiran Acute hepatic porphyrias Approved FDA approval announced November 20, 2019.
Inclisiran Hyperlipidemia PDUFA PDUFA date December 2020.
VIR-2218 Chronic hepatitis B virus (HBV) Phase 2 Phase 2 preliminary antiviral activity and safety data presented at EASL August 28, 2020.
Lumasiran (ALN-GO1) Primary Hyperoxaluria Type 1 (PH1) PDUFA priority review PDUFA date under priority review December 3, 2020.
Patisiran Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Approved FDA Approval announced August 10, 2018.
ALN-CC5 (cemdisiran) IgA nephropathy Phase 2 Phase 2 top-line data due 2021.
Fitusiran (ATLAS) Hemophilia A/B Phase 3 Phase 3 top-line data due 1H 2021.
Vutrisiran - HELIOS-A ATTR amyloidosis Phase 3 Phase 3 top-line data due 1H 2021.
ALN-AAT02 alpha-1 anti-trypsin deficiency-associated liver disease Phase 1/2 Phase 1/2 initial data released.
Lumasiran (ALN-GO1) ILLUMINATE-B Primary Hyperoxaluria Type 1 Phase 3 Phase 3 top-line released September 30, 2020.
Patisiran APOLLO-B Wild-type ATTR amyloidosis patients with cardiomyopathy Phase 3 Phase 3 enrolment to be completed in 2021.
Lumasiran (ALN-GO1) ILLUMINATE-C Impaired renal function Phase 3 Phase 3 trial data due likely 2021.
ALN-AGT Hypertension Phase 1 Phase 1 trial ongoing.
ALN-TTRsc02 (vutrisiran) - HELIOS-B ATTR amyloidosis with cardiomyopathy Phase 3 Phase 3 trial has been initiated - noted November 22, 2019.
VIR-2703 COVID-19 Phase 1 Human trials to commence around the end of 2020.
$7.83
+0.16  +2.09%
23.8 million
$186.2 million
10/27/2020
Tap to view 4 drugs
Drug Indication Stage News
N91115 Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein Phase 2 Phase 2 data released February 24, 2017 - primary endpoint not met.
ALPN-101 Healthy volunteers Phase 1 Phase 1 presentation at ASH December 8, 2019.
ALPN-202 Advanced Malignancies Phase 1 Phase 1 initiation of dosing announced June 24, 2020.
ALPN-101 Graft Vs Host Disease Phase 1/2 Phase 1b/2 trial is open for enrolment - noted March 30, 2020.
$1.27
-0.14  -9.61%
39.9 million
$50.6 million
10/27/2020
Tap to view 4 drugs
Drug Indication Stage News
ALRN-6924 Peripheral T-cell lymphoma (PTCL) Phase 2a Noted that development to be discontinued - no pivotal trial.
ALRN-6924 and Cytarabine (Ara-C) Acute myeloid leukemia (AML); Myelodysplastic syndrome (MDS) Phase 1b Phase 1/1b trial ongoing.
ALRN-6924 and Paclitaxel Breast cancer Phase 1 Phase 1 has been initiated.
ALRN-6924 Small Cell Lung Cancer (SCLC) Phase 1b Phase 1b/2 final data due 1Q 2021.
$11.78
-0.03  -0.25%
32.9 million
$387.7 million
10/27/2020
Tap to view 6 drugs
Drug Indication Stage News
HepTCell Hepatitis B Phase 2 Phase 2 trial to be initiated in 4Q 2020.
NasoVAX Flu vaccine Phase 2 Phase 2 additional data released March 19, 2019 noted all patients remained seroprotected.
NASOSHIELD Anthrax Phase 1b Phase 1b data due 4Q 2020.
ALT-801 Non-alcoholic steatohepatitis (NASH) Phase 1 Phase 1 trial to be initiated in 4Q 2020.
Intranasal COVID-19 Vaccine COVID-19 vaccine Phase 1 Phase 1 trial to commence 4Q 2020.
T-COVID COVID-19 Phase 1/2 Phase 1/2 data due 4Q 2020.
$26.64
+0.68  +2.60%
62.7 million
$1.7 billion
10/27/2020
Tap to view 8 drugs
Drug Indication Stage News
ALVR106 Hematopoietic stem cell transplantation Phase 1/2 Phase 1/2 trial to be initiated 4Q 2020.
ALVR109 COVID-19 Phase 1 Proof of concept trial to be initiated 4Q 2020.
Viralym-M (ALVR105) BK virus Phase 2 Phase 2 trial planned.
Viralym-M (ALVR105) Cytomegalovirus (CMV) Phase 2 Phase 2 trial planned.
Viralym-M (ALVR105) Prevention of Multi-Virus Infections (BKV, CMV, AdV, EBV, HHV-6, and JCV) Phase 2 Phase 2 trial planned.
Viralym-M (ALVR105) Aleution disease virus (ADV) Phase 3 Phase 3 trial planned.
Viralym-M (ALVR105) Cytomegalovirus (CMV) Phase 3 Phase 3 trial planned.
Viralym-M (ALVR105) Virus-associated hemorrhagic cystitis Phase 3 Phase 3 trial planned for 4Q 2020.
$120.13
-0.63  -0.52%
219.2 million
$26.3 billion
10/27/2020
Tap to view 24 drugs
Drug Indication Stage News
CAEL‐101 AL amyloidosis Phase 3 Phase 3 initiation announced September 14, 2020.
Eculizumab Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) Approved FDA Approval announced June 27, 2019.
ULTOMIRIS (ravulizumab-cwvz) atypical Hemolytic Uremic Syndrome (aHUS) Approved FDA Approval announced October 18, 2019.
ULTOMIRIS (ravulizumab-cwvz) Paroxysmal nocturnal hemoglobinuria (PNH) Approved FDA approval announced December 21, 2018.
Eculizumab Refractory generalized myasthenia gravis (gMG) Approved Approval announced October 23, 2017.
Bevyxxa (betrixaban) Venous thromboembolism (VTE) Prevention Approved FDA Approval noted June 23, 2017.
Cerdulatinib (PRT2070) Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer Phase 2 Phase 2a data presented at ASH December 9, 2019. ORR 48%; 76% in combo cohort.
Andexxa Factor Xa inhibitor reversal agent Approved Prior Approval Supplement (PAS) FDA Approval announced December 31, 2018.
ALXN2040 add-on therapy Paroxysmal nocturnal hemoglobinuria (PNH) Phase 3 Phase 3 trial to be initiated by the end of 2020 with data due 2H 2022.
ALXN2050 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 Phase 2 data due 2H 2021.
AG10 / BBP-265 ATTR-PN Phase 2 Phase 3 trial planned for 2H 2020.
ALXN1840 (WTX101) Wilson disease Phase 3 Phase 3 top-line data due 1H 2021.
ULTOMIRIS (ravulizumab-cwvz) Generalized myasthenia gravis (gMG) Phase 3 Phase 3 trial ongoing.
ALXN1830 Warm autoimmune hemolytic anemia (WAIHA) Phase 1/2 Phase 2/3 trial to be initiated in 2021.
ULTOMIRIS (ravulizumab-cwvz) subcutaneous Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) Phase 3 Phase 3 trial met primary endpoint - June 24, 2020. Regulatory filing due 3Q 2021.
Elamipretide Leber’s hereditary optic neuropathy (LHON) Phase 2 Phase 2 trial did not meet primary endpoint.
Elamipretide Primary mitochondrial myopathy Phase 3 Phase 3 data did not meet primary endpoint - December 20, 2019.
ULTOMIRIS Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) Phase 3 Limited dose-ranging studies to commence 2H 2020, followed by Phase 3 trials in 2021.
Eculizumab Generalized myasthenia gravis (gMG) - children Phase 3 Phase 3 trial has commenced - noted October 23, 2019.
Eculizumab Neuromyelitis Optica Spectrum Disorder (NMOSD) - children Phase 3 Phase 3 trial to commence 2H 2020.
ULTOMIRIS (ravulizumab) - CHAMPION-ALS Amyotrophic lateral sclerosis (ALS) Phase 3 Phase 3 trial initiated March 2020.
ULTOMIRIS (ravulizumab-cwvz) COVID-19 Coronavirus Phase 3 Phase 3 open-label, randomized, controlled trial is underway - noted July 30, 2020.
ALXN2040 C3 Glomerulopathy (C3G) Phase 2 Development discontinued - noted July 29, 2020.
ULTOMIRIS Neuromyelitis Optica Spectrum Disorder (NMOSD) Phase 3 Phase 3 trial underway.
$40.84
-0.72  -1.73%
37 million
$1.5 billion
10/27/2020
Tap to view 3 drugs
Drug Indication Stage News
ALX148 and azacitidine Myelodysplastic syndromes (MDS) Phase 1/2 Phase 1/2 trial to be initiated 4Q 2020.
ALX148 and Keytruda Head and neck squamous cell carcinoma (HNSCC) Phase 2 Phase 2 trial to be initiated 1H 2021.
ALX148 and trastuzumab (Herceptin) Solid Tumors and Lymphoma Phase 2 Phase 1 data to be presented at SITC meeting November 11, 2020.
$13.69
+0.01  +0.07%
34.5 million
$472.3 million
10/27/2020
Tap to view 6 drugs
Drug Indication Stage News
AMAG-423 / Digoxin immune fab (DIF) Severe preeclampsia in pregnant women Phase 2/3 Phase 2/3 trial stopped due to low likelihood of efficacy - August 6, 2020.
Vyleesi (Bremelanotide) Female sexual dysfunction (FSD) Approved FDA approval announced June 21, 2019.
Feraheme Adults with iron deficiency anemia (IDA) Approved Approval for sNDA filing announced February 5, 2018.
Makena - auto injector Reduce the risk of preterm birth in women with a singleton pregnancy Approved Approval announced February 14, 2018.
Makena Preterm birth Phase 3 Advisory Committee voted 9-7 recommending withdrawal from market - October 29, 2019.
Ciraparantag Anticoagulated reversal agent / Healthy volunteers Phase 2 Phase 2b trial planned.
AMGN Amgen Inc.
$223.72
-1.18  -0.52%
585.7 million
$131 billion
10/27/2020
Tap to view 41 drugs
Drug Indication Stage News
Tezepelumab - NAVIGATOR Asthma Phase 3 Phase 3 data due late-2020.
Prolia (denosumab) Glucocorticoid-induced osteoporosis (GIOP) Approved Approval announced May 21, 2018.
KYPROLIS (ASPIRE) Relapsed Multiple Myeloma Approved sNDA approval announced June 11, 2018.
Vectibix (Panitumumab) Wild-Type RAS Metastatic Colorectal Cancer Approved sBLA approval announced June 29, 2017.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) PDUFA Approved September 14, 2017.
Corlanor Chronic Heart Failure Approved Approved April 15, 2015.
Erenumab Migraine Approved Approval announced May 17, 2018.
OTEZLA Scalp Psoriasis Approved FDA approval announced April 2020.
OTEZLA - PSA-006 Psoriatic Arthritis Phase 3 Phase 3 - primary endpoint met.
OTEZLA Behçet’s Disease Approved FDA Approval announced July 19, 2019.
Repatha Cardiovascular disease Approved Approval announced December 1, 2017.
XGEVA Multiple Myeloma Approved sBLA approval announced January 5, 2017.
KYPROLIS (ARROW) Multiple Myeloma Approved FDA approval announced October 1, 2018.
KYPROLIS (ENDEAVOR) Relapsed Multiple Myeloma Approved sNDA approved January 17, 2018.
BLINCYTO Ph+ R/R ALL Approved PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
ABP 798 RITUXAN biosimilar - non-Hodgkin lymphoma PDUFA PDUFA (biosimilar) date December 19, 2020.
ABP 980 (Kanjinti; trastuzumab-anns) Herceptin biosimilar CRL FDA approval announced June 13, 2019.
ABP 710 REMICADE biosimilar - rheumatoid arthritis Approved FDA Approval announced December 6, 2019.
Parsabiv Secondary hyperparathyroidism (SHPT) Approved Approved February 7, 2017.
EVENITY (Romosozumab) Osteoporosis Approved FDA Approval announced April 9, 2019.
Omecamtiv mecarbil GALACTIC-HF Acute heart failure Phase 3 Phase 3 top-line data met primary composite endpoint of reduction in cardiovascular death or heart failure but did not meet secondary endpoint of reduction in cardiovascular death - October 8, 2020. Late breaker at AHA, November 13, 2020
Omecamtiv mecarbil METEORIC-HF Acute heart failure Phase 3 Phase 3 enrollment to be completed early 2021.
AMG 420 Relapsed. Refractory (R/R) Multiple Myeloma (MM) Phase 1 Phase 1 data ASCO June 2, 2019. Overall response rate 70% (7/10) in high dose, 13/42 response across all cohorts.
Nplate (Romiplostim) Immune Thrombocytopenia (Pediatric) Approved FDA approval announced December 14, 2018.
Nplate (Romiplostim) Immune thrombocytopenia (ITP) Approved FDA Approval announced October 18, 2019.
OTEZLA Psoriasis Phase 3 Phase 3 trial met primary endpoint - May 6, 2020.
AMG 594 Healthy volunteers Phase 1 Phase 1 trial is complete. Considering next steps.
AMG 510 Solid tumors Phase 1 Phase 1 update at ASCO May 29, 2020. Objective response rate (ORR) was 12% (3/25) in 960 mg once-daily target dose cohort.
CNP520 Alzheimer’s Disease Phase 2/3 Phase 2/3 trial discontinued due to lack of efficacy.
BLINCYTO Acute lymphoblastic leukemia (ALL) - pediatric Phase 3 Phase 3 enrolment terminated due to treatment benefit over chemo. Primary endpoint of event-free survival met.
AMG 570 Systemic Lupus Erythematosus (SLE) Phase 2 Phase 2 trial is enrolling.
Tezepelumab Chronic obstructive pulmonary disease (COPD) Phase 2 Phase 2 trial is enrolling.
AMG 510 Non-small cell lung cancer (NSCLC) Phase 2 Phase 2 data released October 5, 2020. Objective response rate (primary end point) consistent with previously reported Phase 1 data. Detailed data at IASLC meeting January 26-29, 2021.
AMG 510 CodeBreaK 200 Non-small cell lung cancer (NSCLC) Phase 3 Phase 3 trial is enrolling.
AMG 890 Cardiovascular disease / Elevated Lipoprotein Phase 2 Phase 2 trial has commenced - noted July 28, 2020.
AMG 592 Systemic Lupus Erythematosus Phase 1/2 Phase 1b/2 trial is enrolling - noted July 28, 2020.
AMG 592 Chronic Graft Versus Host Disease Phase 1/2 Phase 1b/2 trial is enrolling - noted July 28, 2020.
AMG 160 Castration-resistant Prostate Cancer Phase 1 Phase 1 data due 2H 2020.
AMG 701 Multiple Myeloma Phase 1 Phase 1 data due 2H 2020.
AMG 757 Small Cell Lung Cancer Phase 1 Phase 1 data due 2H 2020.
Cenicriviroc + Otezla (apremilast) + Firazyr (icatibant) COVID-19 (severe) Phase 2 Phase 2 trial initiation announced August 3, 2020.
$0.84
+0.06  +8.09%
176.5 million
$148.8 million
3.13
10/27/2020
Tap to view 3 drugs
Drug Indication Stage News
Ampion Osteoarthritis of the Knee Phase 3 Phase 3 enrolment has been suspended - noted March 24, 2020.
Optina Diabetic Macula Edema Phase 2b Phase 2b data released May 2015 did not meet endpoints
IV Ampion COVID-19 Phase 1 Phase 1 primary endpoint for safety and tolerability met - September 2020.
$19.91
-0.38  -1.87%
47.5 million
$945.4 million
10/27/2020
Tap to view 2 drugs
Drug Indication Stage News
Naloxone Intranasal Opioid overdose CRL CRL announced February 21, 2017.
Primatene Mist (epinephrine inhalation aerosol) Asthma CRL CRL issued December 27, 2016.
$4.87
+0.01  +0.21%
388.7 million
$1.9 billion
10/27/2020
Tap to view 1 drug
Drug Indication Stage News
Vascepa High Triglycerides With Mixed Dyslipidemia Approved FDA Approval announced December 13, 2019.
$4.71
-0.13  -2.69%
147.5 million
$694.9 million
7.47
10/27/2020
Tap to view 2 drugs
Drug Indication Stage News
IPX203 Parkinson's disease Phase 3 Phase 3 trial ongoing.
K127 Myasthenia Gravis NDA Filing NDA filing planned.
$32.97
+0.89  +2.77%
34.9 million
$1.1 billion
10/27/2020
Tap to view 2 drugs
Drug Indication Stage News
AMT-101 Ulcerative colitis Phase 2 Phase 2 commencement of dosing announced August 27, 2020.
AMT-101 Pouchitis Phase 2 Phase 2 trial planned for 2020.
$27.80
+0.07  +0.23%
27.3 million
$758.9 million
10/27/2020
Tap to view 5 drugs
Drug Indication Stage News
ANB020 - etokimab Moderate-to-severe adult atopic dermatitis Phase 2b Phase 2b data failed to meet primary endpoint - November 8, 2019.
ANB020 - etokimab Severe adult eosinophilic asthma Phase 2a Phase 2b trial initiation postponed.
ANB019 - POPLAR Palmo-plantar pustular psoriasis Phase 2 Phase 2 data due 1Q 2021.
ANB019 Generalized pustular psoriasis Phase 2 Phase 2 data noted 6 of 8 patients achieved primary endpoint of improvement in the clinical global impression scale (CGI) on Day 29 - October 13, 2020.
ANB020 - etokimab Nasal polyps Phase 2 Phase 2 data failed to meet primary endpoints after 8 weeks. 16 week data due by the end of 2020.
$1.17
+0.04  +3.54%
7.4 million
$8.7 million
10/27/2020
Tap to view 2 drugs
Drug Indication Stage News
Inodiftagene - Codex Non-muscle invasive bladder cancer (NMIBC) Phase 2 Phase 2 trial discontinued due to lack of efficacy - November 15, 2019.
Inodiftagene with BCG - Leo Non-muscle invasive bladder cancer (NMIBC) Phase 3 Phase 3 planned for 4Q 2019 or 1Q 2020.
$34.42
-0.22  -0.64%
14.2 million
$489 million
10/27/2020
Tap to view 3 drugs
Drug Indication Stage News
Cingal Osteoarthritis Phase 3 Phase 3 trial did not meet primary endpoint - June 19, 2018. Further trial to be initiated depending on COVID-19.
Monovisc Osteoarthritis Approved Approved Feb 2014
HYALOFAST Cartilage defects of the knee Phase 3 Phase 3 completion of enrolment to be delayed due to COVID-19.
$27.76
-0.75  -2.63%
12.3 million
$341.9 million
10/27/2020
Tap to view 1 drug
Drug Indication Stage News
Purified Cortrophin Gel sNDA Filing Refusal to File (RTF) letter announced April 29, 2020. sNDA to be refiled 1Q 2021.
$2.22
+0.04  +1.83%
23.8 million
$52.8 million
10/27/2020
Tap to view 1 drug
Drug Indication Stage News
Breast cancer vaccine Phase 1
$24.42
-0.55  -2.20%
38.1 million
$931.6 million
10/27/2020
Tap to view 5 drugs
Drug Indication Stage News
ANX005 Guillain-Barré Syndrome Phase 2/3 Phase 2/3 trial to be initiated early 2021 with data due 1H 2023.
ANX005 Warm autoimmune hemolytic anemia (WAIHA) Phase 2 Phase 2 trial to be initiated with data due 2H 2021.
ANX005 Huntington’s disease Phase 2a Phase 2a trial to be initiated with data due 1H 2021.
ANX005 Amyotrophic lateral sclerosis (ALS) Phase 2 Phase 2 trial be be initiated with data due 2H 2021.
ANX007 Geographic atrophy Phase 2 Phase 2 trial to be initiated in 2021.
$5.08
+0.23  +4.74%
6.9 million
$34.9 million
1.36
10/27/2020
Tap to view 2 drugs
Drug Indication Stage News
ANVS401 Alzheimer’s disease Phase 2a Phase 2a data due in 2021.
ANVS401 Alzheimer’s disease (AD) and Parkinson’s disease (PD) Phase 2 Phase 2 initial data due early 2021.
$35.81
-0.05  -0.14%
75.6 million
$2.7 billion
10/27/2020
Tap to view 9 drugs
Drug Indication Stage News
APL-2 subcutaneous Cold agglutinin disease (CAD) Phase 2 Phase 3 trial plan update due 3Q 2020.
APL-2 OAKS Geographic atrophy (GA) associated with age-related macular degeneration (AMD) Phase 3 Phase 3 top-line data due 3Q 2021.
Pegcetacoplan (APL-2) PEGASUS Paroxysmal Nocturnal Hemoglobinuria (PNH) NDA Filing NDA filing announced September 15, 2020.
APL-2 subcutaneous Complement-dependent Nephropathies (CDN) Phase 2 Phase 2 initial data presented at ASN November 8, 2019.
APL-2 PRINCE Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 3 Phase 3 top-line data due 1H 2021.
APL-2 (pegcetacoplan) - DERBY Geographic atrophy (GA) Phase 3 Phase 3 data due 3Q 2021.
APL-9 COVID-19 / Acute respiratory distress syndrome (ARDS) Phase 1/2 Phase 1/2 initiation announced May 28, 2020. Enrolling patients in the randomized, double-blind, controlled part of the trial - noted July 31, 2020.
Pegcetacoplan C3G and IC-MPGN Phase 2 Phase 2 trial to commence by the end of 2020. Phase 3 trial to commence 1H 2021.
Pegcetacoplan Amyotrophic lateral sclerosis (ALS) Phase 2 Phase 2 trial to commence by the end of 2020.
$21.30
-0.84  -3.79%
22.4 million
$477.9 million
10/27/2020
Tap to view 3 drugs
Drug Indication Stage News